Core Viewpoint - Shanghai Xiaofang Pharmaceutical Co., Ltd. has signed a technical entrustment contract with Boji Pharmaceutical Technology Co., Ltd. to assist in the clinical research and registration of the new traditional Chinese medicine "Compound Cèbǎi Tincture" for hair loss treatment, marking a significant step in the company's innovation drug strategy [2][12]. Group 1: Transaction Overview - The transaction does not constitute a major asset restructuring as defined by the relevant regulations and does not involve related party transactions [2]. - The collaboration aims to complete the clinical trials and market registration of the new drug, with no significant impact on the company's operating results for the current year [3][12]. Group 2: Partner Information - Boji Pharmaceutical, established in 2002 and listed on the Shenzhen Stock Exchange in 2015, specializes in providing comprehensive outsourcing services for drug and medical device development [4]. - The company has a registered capital of 381.99 million RMB and has a strong track record in traditional Chinese medicine research and development [4]. Group 3: Project Details - The project involves the development of the traditional Chinese medicine "Compound Cèbǎi Tincture" through a commissioned development approach [5]. - Boji Pharmaceutical is responsible for designing and executing the research plans, conducting clinical trial monitoring, and assisting in the registration application [7]. Group 4: Contractual Terms - The intellectual property generated from the project will belong to Shanghai Xiaofang Pharmaceutical, including clinical trial data and research reports [6]. - The contract will be effective upon signing and will remain valid until the new drug application (NDA) is approved [9]. Group 5: Impact on the Company - The collaboration is expected to leverage the strengths of both companies, enhancing the efficiency and success rate of the product's development, thereby laying a solid foundation for future applications and market entry [12].

Core Viewpoint - The collaboration between Xiaofang Pharmaceutical and Boji Pharmaceutical Technology Co., Ltd. aims to enhance the clinical research and registration of a new traditional Chinese medicine product, thereby improving the efficiency and success rate of the development process [1] Group 1: Company Collaboration - Xiaofang Pharmaceutical has signed a technology entrustment contract with Boji Pharmaceutical to assist in the clinical research and registration of a Class 1 compound medicine [1] - Boji Pharmaceutical is recognized as an industry leader with significant advantages in research and development capabilities, technical accumulation, and clinical resources [1] - The partnership is expected to leverage the strengths of both companies, creating a synergistic effect that will solidify the foundation for subsequent product application and market launch [1]

Core Viewpoint - The company has signed a contract with Boji Pharmaceutical Technology Co., Ltd. to assist in the clinical research and registration of a new traditional Chinese medicine product, Compound Cypra, aiming to complete clinical trials and market launch [1] Group 1 - The company is engaged in the development of traditional Chinese medicine [1] - The collaboration with Boji Pharmaceutical is expected to enhance the company's capabilities in clinical research [1] - The focus is on the clinical trial and registration process for a Class 1 new drug [1]

Core Viewpoint - The collaboration between Xiao Fang Pharmaceutical and Boji Pharmaceutical marks a significant step in the development of innovative drugs, particularly in the clinical research and registration of a new traditional Chinese medicine product [1] Group 1: Partnership Details - Xiao Fang Pharmaceutical has signed a "Technical Entrustment (Development) Contract" with Boji Pharmaceutical to assist in the clinical research and registration of a Class 1 traditional Chinese medicine compound [1] - This partnership is based on a shared strategic development vision, indicating a strong alliance between the two companies [1] Group 2: Strategic Implications - The collaboration is expected to leverage Boji Pharmaceutical's strengths in research and development, technical expertise, and clinical resources, enhancing the efficiency and success rate of the product's development [1] - The partnership aims to establish a solid foundation for the subsequent application and market launch of the product [1]

Core Viewpoint - The company, Xiao Fang Pharmaceutical, has signed a technical entrustment contract with Boji Pharmaceutical to assist in the clinical research and registration of a new traditional Chinese medicine, Compound Cypraea Tincture, which is classified as a Class 1 new drug [1] Group 1 - The collaboration aims to facilitate the completion of clinical trials and the subsequent market launch of the new drug [1] - This transaction does not constitute a major asset restructuring or a related party transaction [1] - The agreement is not expected to have a significant impact on the company's operating results for the current fiscal year [1]

Core Viewpoint - The collaboration between the company and Boji Pharmaceutical Technology Co., Ltd. marks a significant step in the company's strategic development in the innovative drug sector, focusing on the clinical research and registration of a new traditional Chinese medicine product [1] Group 1: Partnership Details - The company has signed a "Technical Entrustment (Development) Contract" with Boji Pharmaceutical, which will assist in completing the clinical research and registration of a Class 1 compound medicine [1] - This partnership is described as a strong alliance based on a shared development strategy, leveraging the strengths of both parties [1] Group 2: Advantages of Collaboration - Boji Pharmaceutical is recognized as an industry leader with significant advantages in research and development capabilities, technical accumulation, and clinical resources [1] - The collaboration is expected to create a synergistic effect, enhancing the research and development efficiency and success rate of the contracted product [1] - This partnership aims to lay a solid foundation for the subsequent application and market launch of the product [1]

Group 1: Research Basic Information - The research object is Xiaofang Pharmaceutical, belonging to the chemical pharmaceutical industry, and the reception time was September 12, 2025. The company's reception staff included the chairman and general manager Fang Zhiguang, the board secretary and financial director Luo Xiaoxu, and the independent director Yu Wei [17] Group 2: Detailed Research Institutions - The reception object was the 2025 semi - annual performance briefing of Shanghai Stock Exchange Roadshow Center Company [20] Group 3: Main Content Innovation and R & D - Xiaofang Pharmaceutical is not limited to traditional external medicine business and has started to layout the innovative drug field, with multiple innovative drug projects in different R & D stages. The company is advancing the R & D of traditional Chinese medicine class - one new drugs, including compound Cacumen Platycladi tincture for treating various types of hair loss and compound Herba Speranskiae Tuberculatae solution for antifungal use [24][27] - The compound Herba Speranskiae Tuberculatae solution was jointly developed with Shanghai University of Traditional Chinese Medicine Affiliated Yueyang Hospital of Integrated Traditional Chinese and Western Medicine before the company's listing, and details can be found in the company's IPO prospectus [29] - The qualification for innovative drug application needs to be scientifically determined based on sufficient pharmaceutical, non - clinical, and clinical research data, and the process is rigorous and complex. The company will disclose major progress in accordance with regulations [30] Overseas Business - The company has obtained the approval number for exporting drugs to Macau, China and has realized sales there. It will gradually explore other overseas markets while being aware of challenges such as differences in national regulations, complex registration processes, localization requirements, and strict quality supervision [27] Product Sales - The company is cautious about new product sales. Once there is a clear sales plan, it will announce it in a timely manner [28] Hospital Cooperation - The company focuses on the development and cooperation of various sales channels. Its products are suitable for sales in medical institutions at all levels. It also actively promotes the industry - university - research cooperation and development of innovative drugs [29]

Group 1 - Xiaofang Pharmaceutical announced a collaboration with Shanghai Skin Disease Hospital to develop a new traditional Chinese medicine for hair loss, Compound Cèbǎi Tincture, which is expected to be the first TCM formulation for hair loss in China [1] - Guizhou Sanli plans to invest 150 million RMB in a patent transfer and technical cooperation contract with Guangdong Pharmaceutical University for the development of a new TCM drug [1] - The technical cooperation will involve a total development cost of 100 million RMB for the research and development of SL&GDPU-001, a new TCM drug [2] Group 2 - Jichuan Pharmaceutical's actual controller, Cao Longxiang, transferred part of his equity in Jichuan Holdings to his son, Cao Fei, which is an internal family equity adjustment and will not affect the company's independence [2] - Junshi Biosciences received acceptance for the clinical trial application of JT118 injection, a vaccine aimed at preventing monkeypox virus infection, marking a significant step as no such vaccine has been approved in China [3] - Palin Bio announced that its controlling shareholder, Shengbang Yinghao, intends to transfer 21.03% of its shares to China National Pharmaceutical Group, which will result in a change of control [3] Group 3 - East China Pharmaceutical's subsidiary received FDA approval for the clinical trial of HDM1010 tablets, aimed at treating type 2 diabetes, enhancing the company's competitiveness in the endocrine field [4]

Industry News - The Ministry of Commerce has approved a certain number of compliant applications for rare earth-related export licenses, considering the reasonable needs and concerns of various countries in the private sector [6] - Ant International plans to apply for a stablecoin license in Hong Kong following the passage of the Stablecoin Bill, with the application to be submitted as soon as the relevant channels are opened [8] - The People's Bank of China and the State Administration of Foreign Exchange have issued measures to support the integration and development of cross-strait relations, proposing 12 policy measures to enhance financial support [8] - The Hong Kong Securities and Futures Commission is studying adjustments to the number of shares per transaction to improve the convenience of trading high-priced and fractional shares, thereby enhancing market liquidity [8] - The Guangxi Zhuang Autonomous Region has launched a special action plan to boost consumption, focusing on subsidies for the replacement of old vehicles and home appliances [8] - Urumqi plans to invest 44.815 billion yuan in 82 cultural tourism projects by 2025, with a focus on attracting high-end hotel clusters and creating comprehensive cultural tourism spaces [8] Company News - Xinhua Insurance plans to invest no more than 15 billion yuan to subscribe for private equity fund shares [11] - Vanke A announced the sale of 72.96 million A-shares from June 10 to June 12 to supplement the company's liquidity [12] - ST Gongzhi's stock will be delisted as per the Shenzhen Stock Exchange's decision [13] - ST Jinyi announced the removal of other risk warnings, with trading resuming on June 16 [14] - China Power Construction announced it won a 10.77 billion yuan EPC contract for an offshore wind power project [15] - Taiji Co., Ltd. announced that its controlling shareholder is planning a change in company control, leading to a stock suspension [17]

Core Viewpoint - The company Xiaofang Pharmaceutical (603207) is officially entering the field of traditional Chinese medicine compound preparation new drug development by collaborating with Shanghai Dermatology Hospital to develop a new product for hair loss treatment [2][3]. Group 1: Collaboration and Product Development - Xiaofang Pharmaceutical has signed a cooperation agreement with Shanghai Dermatology Hospital to jointly develop a new drug, Compound Cèbǎi Tincture, aimed at treating various types of hair loss [2]. - The collaboration aims to obtain the new drug (Class 1.1) market approval from the National Medical Products Administration, involving preclinical research and clinical trials [2][3]. - The company will pay a total of 20 million yuan for technology transfer and support, with additional sales commissions after the product is launched [2]. Group 2: Market Potential and Strategic Focus - According to the National Health Commission, the number of people suffering from hair loss in China has exceeded 250 million, with a noticeable increase in younger demographics aged 20-40 due to economic and lifestyle pressures [2]. - The Compound Cèbǎi Tincture has been well-received by patients and shows promising development prospects, potentially becoming the first traditional Chinese medicine preparation for hair loss in China [3]. - Xiaofang Pharmaceutical has a strong focus on over-the-counter external medications and aims to expand its product pipeline while optimizing research and development structures to meet family health needs [3].